Guideline
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents - European Society for Medical Oncology (ESMO)
Abiraterone acetate with prednisone improved MFS and OS for very-high-risk localised prostate cancer undergoing RT and ADT.
Combining ADT with docetaxel–abiraterone–prednisone in men with de novo mHSPC improved both rPFS and OS versus ADT–docetaxel.
Combining ADT with docetaxel and darolutamide in men with mHSPC improved OS versus ADT–docetaxel.
Olaparib improved OS in men with mCRPC and BRCA alterations post-novel androgen receptor axis inhibitor.
Cabazitaxel in men with mCRPC post-novel androgen receptor axis inhibitor and docetaxel improved both rPFS and OS.
177Lu-PSMA-617 in men with mCRPC post-novel androgen receptor axis inhibitor and taxanes improved both rPFS and OS.
Read full guideline